KAIRA Trademark

Trademark Overview


On Friday, August 12, 2022, a trademark application was filed for KAIRA with the United States Patent and Trademark Office. The USPTO has given the KAIRA trademark a serial number of 79351233. The federal status of this trademark filing is REGISTERED as of Tuesday, May 28, 2024. This trademark is owned by OPTOLANE TECHNOLOGIES INC.. The KAIRA trademark is filed in the Pharmaceutical Products category with the following description:

Reagents for measurement of HBs antibody; glue coated strips for use against vermin; medicine cases, portable, filled, namely, medical diagnostic kits consisting primarily of clinical medical reagents being oligonucleotides, enzymes, and nucleotides, and also containing DNA primers and biochemical probes, fluorescent reference dye, and reaction buffers for nucleic acid genotyping, nucleic acid quantification and nucleic acid amplification, and polymerase chain reaction and reverse transcription polymerase chain reaction for use in clinical laboratories, hospitals, point-of-care and direct consumer applications; medical diagnostic reagents for immunization disease; mothproofing paper; bacterial preparations for veterinary purposes; reagent paper for veterinary purposes; reagents for use in veterinary genetic testing; milk sugar for pharmaceutical purposes; medicated plasters; cultures of microorganisms for medical use in dietary supplements and food supplements; reagent paper for medica...
kaira

General Information


Serial Number79351233
Word MarkKAIRA
Filing DateFriday, August 12, 2022
Status700 - REGISTERED
Status DateTuesday, May 28, 2024
Registration Number7393879
Registration DateTuesday, May 28, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 12, 2024

Trademark Statements


Goods and ServicesReagents for measurement of HBs antibody; glue coated strips for use against vermin; medicine cases, portable, filled, namely, medical diagnostic kits consisting primarily of clinical medical reagents being oligonucleotides, enzymes, and nucleotides, and also containing DNA primers and biochemical probes, fluorescent reference dye, and reaction buffers for nucleic acid genotyping, nucleic acid quantification and nucleic acid amplification, and polymerase chain reaction and reverse transcription polymerase chain reaction for use in clinical laboratories, hospitals, point-of-care and direct consumer applications; medical diagnostic reagents for immunization disease; mothproofing paper; bacterial preparations for veterinary purposes; reagent paper for veterinary purposes; reagents for use in veterinary genetic testing; milk sugar for pharmaceutical purposes; medicated plasters; cultures of microorganisms for medical use in dietary supplements and food supplements; reagent paper for medical purposes; reagents for use in medical genetic testing; preparations for detecting mutation in prion genes for medical purposes; chemical reagents for medical purposes; medical diagnostic reagents; chemical preparations for the diagnosis of pregnancy; diagnostic biomarker reagents for medical purposes; lining materials for dental purposes; Diagnostic preparations for medical purposes in the nature of preparations for diagnosing tuberculosis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 30, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOPTOLANE TECHNOLOGIES INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressKR

Party NameOPTOLANE TECHNOLOGIES INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressKR

Party NameOPTOLANE TECHNOLOGIES INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events


Event DateEvent Description
Thursday, September 29, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, September 30, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 4, 2022APPLICATION FILING RECEIPT MAILED
Thursday, June 1, 2023ASSIGNED TO EXAMINER
Thursday, June 15, 2023NON-FINAL ACTION WRITTEN
Friday, June 16, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 21, 2023REFUSAL PROCESSED BY MPU
Friday, July 21, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, August 15, 2023REFUSAL PROCESSED BY IB
Tuesday, January 9, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 9, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 9, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 5, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 21, 2024NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, February 21, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 21, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 21, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 6, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 6, 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, March 11, 2024NOTIFICATION PROCESSED BY IB
Tuesday, March 12, 2024PUBLISHED FOR OPPOSITION
Tuesday, March 12, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, March 25, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, May 28, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, May 28, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Wednesday, August 28, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sunday, November 10, 2024FINAL DISPOSITION NOTICE SENT TO IB
Saturday, November 30, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Sunday, November 10, 2024FINAL DISPOSITION PROCESSED